Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody
Plasma Cell Myeloma
Explore 475 assets in Plasma Cell Myeloma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Keymed Biosciences Co.Ltd
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06126237CT.gov A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04818372CT.gov Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody (this asset) | Keymed Biosciences Co.Ltd | P1/2 | CC · 45 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-cd38-adp-ribosyl-cyclase-1-cyclic-adp-ribose-hydrolase-1-cadpr-hydrolase-1-cadpr1-humanized-monoclonal-antibody-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →